James Bilsborrow, a Weitz & Luxenberg partner and practice group co-chair, is speaking at a virtual event titled “PFAS Litigation and Regulatory Developments Conference.” It…
Read MoreFirm News: Dec. 2015
Category: Our Firm, Personal Injury
W&L Obtains Substantial Settlement in Challenging Negligence Case
Weitz & Luxenberg last month obtained a confidential multimillion-dollar settlement on behalf of a Queens, New York, man who sustained a traumatic brain injury, as well as other injuries, after falling from an apartment building’s second story walkway next to an apartment. The settlement came on the heels of a hard-won appellate victory that W&L…
Category: Drugs & Devices
Pennock Takes Leadership Role in First PSC with Woman Majority in Power Morcellator MDL Litigation
On November 18, 2015, U.S. District Judge Kathryn H. Vratil of Kansas appointed the first plaintiffs steering committee (PSC) in a federal multidistrict litigation (MDL) with a majority of women members. This is a significant and appropriate achievement given that women comprise a large segment of the lawyers in the United States and about 50…
Category: Drugs & Devices
W&L Adds Serious Urinary Tract Infections to SGLT2 Inhibitor Injuries Probe
Weitz & Luxenberg, P.C., today announced that the firm has expanded the scope of its investigation into SGLT2 inhibitor drug injuries. SGLT2 inhibitor drugs include Invokana and others listed below. This move will allow the nationally known mass tort law and personal injury firm to focus on cases where people taking SGLT2 inhibitors were hospitalized…